United States: A Sufficient Controversy Exists When A Second ANDA Filer Seeks DJ Of Noninfringement Of An Orange-Book-Listed Patent Owned But Disclaimed By Brand Name Manufacturer

In Apotex Inc. v. Daiichi Sankyo, Inc., Nos. 14-1282, -1291 (Fed. Cir. Mar. 31, 2015), the Federal Circuit reversed the district court's dismissal of Apotex, Inc.'s ("Apotex") complaint for DJ that Apotex will not infringe an Orange-Book-listed patent owned but disclaimed by Daiichi Sankyo, Inc. and Daiichi Sankyo Co., Ltd. (collectively "Daiichi") if Apotex manufactures or sells a generic drug bioequivalent of Daiichi's Benicar®.  The Federal Circuit also reversed the district court's denial of Mylan Pharmaceuticals, Inc.'s ("Mylan") motion to intervene.

Daiichi listed two patents in the Orange Book to cover Benicar®.  The first, U.S. Patent No. 5,616,599 ("the '599 patent"), covers the active ingredient of the drug, olmesartan medoxomil, and expires on April 25, 2016.  Daiichi's second listed patent, U.S. Patent No. 6,878,703 ("the '703 patent"), covers methods of treatment and expires on November 19, 2021.

Mylan filed an ANDA in April 2006, certifying that both patents were invalid or would not be infringed by Mylan's proposed drug.  Thereafter, Daiichi disclaimed all claims of the '703 patent and asked the FDA to remove the '703 patent from the Orange Book.  The FDA did not remove the '703 patent from the Orange Book.  Daiichi sued Mylan for infringing the '599 patent.  The district court in that case upheld the validity of the '599 patent and entered judgment of infringement against Mylan.  As such, Mylan's earliest date of market entry is October 25, 2016, six months after the expiration date of the '599 patent. 

After the litigation was over, Apotex filed its own ANDA and two certifications under 21 U.S.C.
§ 355(j)(2)(A)(vii):  (1) a Paragraph III certification accepting the result of the prior Mylan litigation with respect to the '599 patent; and (2) a Paragraph IV certification stating that Apotex's product would not infringe the '703 patent.  Daiichi did not sue Apotex for infringing the '703 patent.  Apotex brought a DJ action, seeking a declaration that its product would not infringe the disclaimed, but still listed, '703 patent.  Mylan moved to intervene, and both it and Daiichi moved to dismiss Apotex's complaint.  The district court granted Daiichi's motion to dismiss and denied Mylan's motion to intervene as moot.  Apotex appealed, and Mylan cross-appealed the denial of its motion to intervene.

On appeal, the Federal Circuit first confirmed Mylan's right to intervene.  To the Court, Apotex seeks to cause a forfeiture of Mylan's presumed market-exclusivity period, and Mylan has a strong, concrete monetary interest in retaining such exclusivity—180 days of more sales and/or higher prices than are likely when Apotex enters the market.  The Court explained that, although Daiichi likely benefits from the exclusivity period as well, Mylan's interest exists apart from that of Daiichi.

"The patent disclaimer eliminates one, but only one, potential legal barrier to Apotex's ability to make [sales of olmesartan medoxomil] sooner rather than later.  The listing of the patent, with its current consequence of preventing FDA approval during Mylan's presumptive exclusivity period, is another, and the parties have adverse concrete interests in the truncation or preservation of that period."  Slip op. at 10.

The Federal Circuit then reversed the district court's dismissal of Apotex's complaint for lack of a case or controversy, concluding that "the facts alleged, under all the circumstances, show that there is a substantial controversy, between parties having adverse legal interests, of sufficient immediacy and reality to warrant the issuance of a declaratory judgment."  Slip op. at 9 (quoting MedImmune, Inc. v. Genentech, Inc., 549 U.S. 118, 127 (2007)).  In reaching this conclusion, the Federal Circuit addressed the following four issues.

First, the Federal Circuit rejected Daiichi's contention that its statutory disclaimer of the '703 patent itself means that there is no adversity between it and Apotex over stakes of a concrete character.  To the Court, the concrete stakes over which Daiichi and Apotex were fighting are the revenues to be earned through selling olmesartan medoxomil.  The patent disclaimer only eliminates one of the potential legal barriers to Apotex's ability to make such sales sooner rather than later.  The listing of the '703 patent, with the current consequence of preventing FDA approval during Mylan's presumptive exclusivity period, is another legal barrier, and the parties have adverse concrete interests in truncating or preserving that period.  The Court also explained that all three parties were likely affected by whether Apotex can cause the forfeiture of Mylan's exclusivity period.  As explained by the Court, once Apotex enters the market, Daiichi and Mylan can expect to lose sales they otherwise would have made. 

Second, the Federal Circuit held that Daiichi was also wrong in asserting that the delayed entry of Apotex is not "fairly traceable" to Daiichi.  Id. at 12.  The Court explained that a first filer's eligibility for marketing exclusivity is expressly conditioned on its ability to "lawfully maintain[]" a Paragraph IV certification.  Id. (alteration in original) (quoting 21 U.S.C. § 355(j)(5)(B)(iv)(II)(bb)).  According to the Court, Daiichi's original listing of the '703 patent in the Orange Book supports Mylan's exclusivity period.  Had Daiichi not listed the '703 patent in the Orange Book, the '599 patent would be the only listed patent, and Mylan would have no exclusivity period.  Thus, the Court concluded that Daiichi was responsible for the current existence of Mylan's exclusivity-period rights.

Third, the Federal Circuit decided that Apotex did not have to wait until it obtains tentative FDA approval of its proposed drug to support an adjudication of the request for a noninfringement judgment.  The Court explained that the congressional judgment embodied in the Hatch-Waxman Act and the Court's case law make clear that "tentative approval of an ANDA is generally not a precondition to the existence of a case or controversy concerning patents listed in the Orange Book."  Id. at 18.

Fourth, the Federal Circuit highlighted the two requirements for forfeiture under the Medicare Prescription Drug, Improvement, and Modernization Act of 2003—a court's final decision of noninfringement that is no longer appealable (certiorari aside) and the second (or later) filer's receipt of tentative FDA approval.  The first filer forfeits its exclusivity if it has not entered the market seventy-five days after those two requirements are satisfied.  The Court concluded that Apotex can trigger forfeiture by obtaining a DJ of noninfringement and tentative approval, if it does both early enough in relation to Mylan's market entry. 

The Federal Circuit rejected Mylan's argument that the second filer must have tentative approval before it initiates the DJ action and stressed that no such requirement could be found in the statutory text.  To the Court, tentative approval is required to trigger forfeiture, and Apotex's approval status when it brought the DJ action is immaterial.  The Court also rejected Mylan's argument regarding the statutory policy underlying the exclusivity period, emphasizing that the exclusivity period encourages early entry by generics into the market by providing a reward to first filers, but only up to a point.  Finally, the Court distinguished the instant case from Teva Pharmaceuticals USA, Inc. v. Sebelius, 595 F.3d 1303 (D.C. Cir. 2010), by pointing out that the forfeiture Apotex sought to produce would not be effected by Daiichi's unilateral action but by a court judgment.  

Judges: Taranto (author), Mayer, Clevenger

[Appealed from N.D. Ill., Judge Coleman]

This article previously appeared in Last Month at the Federal Circuit, April, 2015

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Copyright © 2015 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP | All rights reserved

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Events from this Firm
27 Nov 2017, Seminar, London, UK

Finnegan partner Anthony Tridico will present “U.S. Patent Case Law Update” at the Chartered Institute of Patent Attorneys’ annual Patent Case Law Review.

28 Nov 2017, Seminar, Milan, Italy

Finnegan partner John Paul will present “Internet of Things: Patent Liability, Enforcement and Licensing” and will join the Mock WIPO Mediation at International Technology Transfer—Licensing and ADR, co-hosted by Licensing Executives Society and World Intellectual Property Organization.

29 Nov 2017, Seminar, Tel Aviv, Israel

Finnegan is a platinum sponsor IVC Research Center’s start-up forum, “The Most Promising Start Ups for 2017 – A Synergy of Big Data, Artificial Intelligence, Machine Vision and IoT.”

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

*** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.